Browse: Home / Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

Menu

Skip to content
  • Home
  • About Us
  • Contact Us
  • Submit News
Header image

Cambodian TribuneLogo

Latest Cambodian News

Menu

Skip to content
  • Misc
  • Affairs
  • Information
  • Fashion
  • Self Care
  • Athletic
  • Domestic Affairs
  • Legal
  • PRESS RELEASES
  • PM Hun Sen Highlights Government Policy of "One Province, One University"
  • PM Admires All Cambodian Athletes Joining the 30th SEA Games
  • AKP, VNA Agree to Further Strengthen Bilateral Cooperation
  • H.E. Prak Sokhonn to Attend 14th ASEM Foreign Ministers' Meeting in Spain
  • Cambodia Dismayed by Designation of Cambodian Nationals under Global Magnitsky Act

Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

Posted by admin on September 16, 2014 in Health Care | 16 Views

SAN DIEGO, Sept. 17, 2014 /PRNewswire/ — Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company (NYSE: LLY). Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

Logo – http://photos.prnewswire.com/prnh/20140820/138306

Lilly developed enzastaurin in a variety of indications, including in Phase 2 and Phase 3 clinical trials for diffuse large B-cell lymphoma (DLBCL). In studies conducted by Lilly, enzastaurin achieved promising clinical results in the DLBCL induction setting in Phase 2 trials, but did not meet the primary endpoint in the DLBCL maintenance setting in the Phase 3 study.  A meaningful subset of patients showed significantly improved progression-free survival and Denovo Biopharma intends to conduct genetic analysis to identify biomarkers that are related to this outcome. By identifying genomic biomarkers that correlate with patients’ responsiveness to treatment, Denovo plans to screen for appropriate patient subsets for enrollment in future clinical trials that the company plans to conduct.

"We appreciate Lilly’s extensive efforts in the development of enzastaurin to date.  As our first late-stage asset acquired from a premier pharmaceutical company, this high quality data package will enable Denovo to conduct our retrospective biomarker discovery," said Michael F. Haller, Ph.D., Denovo Biopharma’s Chief Operating Officer.  "Our biomarker discovery efforts take only a few months, so when combined with Lilly’s existing data package, we should be able to rapidly initiate a biomarker validation clinical trial for the original indication (DLBCL). We are actively seeking to acquire additional drugs in late-stage development where we can utilize our biomarker discovery platform to personalize and advance other potential treatments in similar fashion."

About Enzastaurin

Enzastaurin (DB102, formerly LY317615 HCl) is an investigational oral small molecule, serine/threonine kinase inhibitor of the PKC beta and AKT pathways [1] [2] and has been studied in more than 3,000 patients across a range of solid and hematological tumor types. Diffuse large B-cell lymphoma occurs in approximately 25,000 patients annually in the U.S. Enzastaurin has received orphan drug designation from the FDA and EMA.

About Denovo Biopharma

Denovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to personalized drug development, including re-evaluating medicines that have failed in general patient populations by personalizing them for the original indication. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology may be especially useful for compounds with suboptimal late-stage trial results.  By identifying biomarkers correlated with patients’ responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. For additional information please visit www.denovobiopharma.com.

Contact:
Michael Haller, Chief Operating Officer
Denovo Biopharma, LLC
(858) 876-4012
mhaller@denovobiopharma.com

[1] Graff JR, et al. Cancer Res. 2005; 65:7462-7469
[2] Brautigam K, et al. Transl Oncol. 2009; 2; 164-173.

Posted in Health Care | Tagged BIO, HEA, MTC, PDT, PHA, TRI

Related Posts

Missing imageDKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia→

Missing imageSphenopalatine Ganglion Stimulation in the Pathway CH-1 Study Reduces Headache Burden Before and After Sustained Periods of Cluster Attack Remission→

Missing imageLatin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities→

Missing imageChinese doctors get admiration for free treatment in Cambodia (China Daily)→

Search

Pages

  • Home
  • About Us
  • Contact Us
  • Submit News

Categories

Calendar

December 2019
M T W T F S S
« Nov    
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Advertisement

Latest News

  • Missing image

    PM Hun Sen Highlights Government Policy of “One Province, One University”

    December 11, 2019 / admin
  • Missing image

    PM Admires All Cambodian Athletes Joining the 30th SEA Games

    December 11, 2019 / admin
  • Missing image

    AKP, VNA Agree to Further Strengthen Bilateral Cooperation

    December 11, 2019 / admin
  • Missing image

    H.E. Prak Sokhonn to Attend 14th ASEM Foreign Ministers’ Meeting in Spain

    December 11, 2019 / admin
  • Missing image

    Cambodia Dismayed by Designation of Cambodian Nationals under Global Magnitsky Act

    December 10, 2019 / admin
  • Missing image

    Korea Provides Weather Observation Assistance to Cambodia

    December 10, 2019 / admin
  • Missing image

    Cambodia Hosts 19th VECONAC General Assembly

    December 10, 2019 / admin
  • Missing image

    PM: Cambodians Regain Full Rights after Country’s Liberation from Khmer Rouge Regime

    December 10, 2019 / admin
  • Missing image

    Cambodia to Attend 2nd APA Executive Council Meeting and 12th APA Plenary in Turkey

    December 9, 2019 / admin
  • Missing image

    Phnom Penh-Sihanoukville Expressway Construction Project Achieved by Over 7 Percent

    December 9, 2019 / admin
  • Facebook
  • Pinterest
  • Tumblr
  • Twitter

Pages

  • About Us
  • Contact Us
  • Submit News

Categories

 

Recent Posts

  • PM Hun Sen Highlights Government Policy of “One Province, One University” December 11, 2019
  • PM Admires All Cambodian Athletes Joining the 30th SEA Games December 11, 2019
  • AKP, VNA Agree to Further Strengthen Bilateral Cooperation December 11, 2019
 

Search

Archives

 

About Us

Cambodia Tribune is a website which acts as an information bank in which news and press releases from various sources are updated on a regular basis. The information is associated with Cambodia and features national news, business news, technological news and other news coverage.
 

©2019 Cambodian Tribune

Menu

  • Home
  • About Us
  • Contact Us
  • Submit News